Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Outstanding: 114,144,104 for January 5, 2023
Monthly 5th Report
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_Jan_5_2023.pdf?4ag8fUlPnuf7dtM7ONzIV7VEEkwBDyXt
North Louisiana Forensic Science Center to host Cannabix Marijuana Breathalyzer Technology/b]
Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety[
https://www.otcmarkets.com/stock/BLOZF/news/story?e&id=2417549
Outstanding Shares 690,499,016 posted 01/03/2023
https://www.otcmarkets.com/stock/MEDH/security
“Reg A+ financings continue to be a very successful way of raising capital by allowing the innovative online and digital marketing of securities to the general public on a global scale,” said Christopher J. Moreau, CEO of AGN Pharma. “By creating AGN Neuro with the sole focus of advancing the DMT stroke research program through its future clinical trials, we are working to create an exciting new investment vehicle with the goal of enhancing shareholder value in the process.”
https://webfiles.thecse.com/AGNnr010323.pdf?ezrw212gYlQb30YKNz2VT4UqXogdjqqw
Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Forms-Private-Subsidiary-to-Advance-Companys-Psychedelic-DMT-Stroke-Program-Files-Form-1-A-Offe?id=385193
Hans just tweeted — Name change to Dazed, Inc and Symbol change to $DAZE has been Approved
$DAZE make’s me DAZED
Outstanding 2,385,332 on December 6, 2022
Monthly 5th Report
https://webfiles.thecse.com/11._Algernon_-_CSE_Form_7_-_November.pdf?Dz14dceUzOdrh6fW5PExka6QghRygd0Z
Outstanding: 114,144,104 for December 5, 2022
Monthly 5th Report
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_Dec_5_2022.pdf?S9LQvZtPXCwdqPAwaRrnhOTWU38DEpnm
Outstanding Shares 690,499,016 posted 12/01/2022
https://www.otcmarkets.com/stock/MEDH/security
So what happens to your beef if the Symbol Change happens
I guess that would prove Hans has control of the Company — Don’t you think ?
Got an update regarding ticker symbol change from $medh => $daze. FiNRA is requesting additional info.. no biggie.. we're working on it and should be done soooooooon! #soon #OTC #cannabisnews #investors @DazedBrands @lazydazeco
https://mobile.twitter.com/the1onlyhans
I think the Dollar’$ are gonna holler and for my Birthday - $BLOZF sent me a CAB on my B-Day
I think that will make us Dollar’$ someday
Happy Holidays to you — more to come
$BLOZF gonna $BLO
MarketOne Video Interview with CEO Christopher J. Moreau - Algernon Pharmaceuticals is the First to Investigate DMT as a Treatment for Stroke
Outstanding 2,385,332 on November 14, 2022
Monthly 5th Report - Outstanding jumped 27,000+
https://webfiles.thecse.com/10._Algernon_-_CSE_Form_7_-_October.pdf?PHCH2qPmpQB.oqaEbiA78pWedp0LxJnW
Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study
VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”) in the Netherlands. The trial will be conducted at the Centre for Human Drug Research (“CHDR”) in Leiden. DMT is a known psychedelic compound that is part of the tryptamine family. The company plans to open enrollment shortly and dose the first subject of the study in December 2022.
The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion, for durations which have never been studied clinically. In addition, several pharmacodynamic measures believed to be associated with neuroplasticity, including both measurements of biochemical markers and electroencephalographic readings, will be recorded.
The first part of the study will use a single-escalating dose design, aimed at identifying a safe and tolerable dose that will not produce psychedelic effects, while the second part will test the effects of repeated administrations of this dose. There will be up to 60 healthy volunteers enrolled across the two parts of the study which will include both psychedelic experienced and psychedelic naïve patients.
Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study. The resulting data generated will help the Company to plan both its Phase 2 acute stroke and rehabilitation studies more effectively.
The Company’s decision to investigate DMT and move it into human trials for stroke is based on multiple independent, positive preclinical studies demonstrating that DMT, at a sub-psychedelic dose, helps promote structural and functional neuropasticity. These are key factors involved in the brain’s ability to form and reorganize synaptic connections, which are needed for healing following a brain injury.
“We are very excited to be initiating our DMT clinical stroke research program with our Phase 1 study at CHDR in the Netherlands,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “The preclinical data shows that DMT promotes the production of brain-derived neurotrophic factor which is an important part of the brain’s recovery process after an injury like a stroke.”
About DMT
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals including humans and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazon basin. DMT can also be synthesised in a laboratory.
Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy.
About Algernon Pharmaceuticals Inc.
Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs. Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
Processing Fees for NV Cannabis Lounges
A one-time, non-refundable processing fee of $100,000 is required for an application for a retail cannabis consumption lounge. A one-time, non-refundable processing fee of $10,000 is required for an application for an independent cannabis consumption lounge.
https://www.wecannca.com/nevada-consumption-lounge-license-application-info/
News: Warren County, PA Police to Pilot Cannabix Marijuana Breathalyzer Technology
https://mailchi.mp/cannabixtechnologies/news-16101329?e=e478252e25
LazyDaze ABQ
https://media-exp1.licdn.com/dms/image/C5622AQE9B65VGeneew/feedshare-shrink_800/0/1666998483378?e=1670457600&v=beta&t=ty42U_m7uBDm-1kUiA6OHPTKUVEgVEuac6a_zuyq_dg
Looking @ the 4 who’s listed as Officers - All connected to Dazed Inc list of folks on Dazed Inc as Officers
https://www.dazedinc.com/about-dazedinc
https://opencorporates.com/companies/us_nv/E26881792022-6/officers
Name and ticker change soon?
Name and ticker change soon?
— Evilbetty (@Evilbetty01) November 6, 2022
We @DazedBrands $medh @lazydazeco will be at #MJBizCon next week. Let's set up some meetings, pow wows, coffee, beer and build some bridges. Lots to cover. Seeking new suppliers, relationships, white labels and networking. #LFG
We @DazedBrands $medh @lazydazeco will be at #MJBizCon next week. Let's set up some meetings, pow wows, coffee, beer and build some bridges. Lots to cover. Seeking new suppliers, relationships, white labels and networking. #LFG pic.twitter.com/3rDxqI9lgK
— the 1 & Only HANS (@The1OnlyHans) November 6, 2022
Outstanding: 114,144,104 for November 5, 2022
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_Nov_5_2022.pdf?XsBS1q1Bx6o3jcB.SyicI0pBl_TYlJ5k
Why Algernon Believes it is the Janis Joplin of Psychedelic Medicine Companies
https://www.drugdiscoverytrends.com/why-algernon-believes-it-is-the-janis-joplin-of-psychedelic-medicine-companies/
Personally I’d like more Quarters right now but that $1 will come and shoot for $5 but watch the all time high to be a switch, this will be played as always with the flip to flip to flip and then that all time high, it’ll look as a flip but is rather for those doing it with them but not a insider —- So they buy up those following their flip and they gather more of a Hold
Breathalyzer Gonna happen in a lot of ways
JMO
$BLOZF Gonna $BLO
Outstanding Shares 690,499,016 posted 11/01/2022
https://www.otcmarkets.com/stock/MEDH/security
Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 Study of DMT for Stroke
Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Enters-into-a-Clinical-Trial-Agreement-with-Yale-University-for-a-DMT-Phase-2-Depression-Study?id=377158
Contactless Alcohol Breath Detection Technology for Workplace and Vehicles
https://www.otcmarkets.com/stock/BLOZF/news/story?e&id=2352187
Cannabix Technologies to Participate in October Southern US Study using Marijuana Breathalyzer Technology
https://cannabixtechnologies.com/investors/news-releases/cannabix-technologies-to-participate-in-october-southern-us-study-using-marijuana-breathalyzer-technology/
Prolonged DMT Infusions could be a Breakthrough for Stroke Patients
https://psychedelicspotlight.com/prolonged-dmt-infusions-could-be-a-breakthrough-for-stroke-patients/
DMT pioneer Rick Strassman weighs in on psychedelic hope and hype
https://www.drugdiscoverytrends.com/dmt-pioneer-rick-strassman-weighs-in-psychedelic-hope-and-hype/
Outstanding: 114,144,104 for October 5, 2022
Monthly 5th Report
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_Oct_5_2022.pdf?NnpgdX7mchNx5INp3_AAAZZt7wut43zU
HIGH TIMES — New Research Exploring DMT as a Treatment for Stroke
https://hightimes.com/psychedelics/new-research-exploring-dmt-as-a-treatment-for-stroke/
Medx Holdings Announces Name Change to Dazed Inc.
Outstanding Shares 690,499,016 posted 10/03/2022
https://www.otcmarkets.com/stock/MEDH/security
Approval to Conduct DMT Study in the Netherlands
https://mugglehead.com/algernon-receives-approval-to-conduct-dmt-study-in-the-netherlands/
Orphan Drug Status Sought for NP-120 to Treat IPF With Cough
https://pulmonaryfibrosisnews.com/news/orphan-drug-status-sought-ipf-therapy-np-120-treat-cough/
You are Invited to Attend a Webinar Presentation, Deep Dive and Q & A with Algernon Pharmaceuticals CEO Christopher J. Moreau
Tuesday, September 27th @ 12:30PM ET / 9:30AM PT
Attendees will be able to ask the CEO questions during the Webinar. After registering through the link at the bottom of this message, you will receive a confirmation email about joining the webinar.
Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs. Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke. Website: https://algernonpharmaceuticals.com/
Market Radius Research gives individual investors access to in-depth CEO interviews with deep-dive institutional-level discussion and Q&A. Market Radius is hosted by Martin Gagel, former top-ranked sell-side technology and special sits analyst. By registering for this webinar you agree to receive a weekly email from Radius Research (with one-click unsubscribe if you're not interested) and your contact information will be shared with the presenting company.
Please find the public registration link below for our webinar Tuesday, September 27th at 12:30PM ET / 9:30AM PT.
Webinar Registration Link
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
$AGNPF Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Files-for-Orphan-Designation-with-the-US-FDA-for-Ifenprodil-as-a-Treatment-of-IPF?id=372858
Approval for Groundbreaking Phase 1 DMT Human Stroke Study
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Receives-Approval-for-Groundbreaking-Phase-1-DMT-Human-Stroke-Study?id=372049